Severe generalized exanthema due to etanercept given for severe plaque psoriasis.

[1]  A. Gottlieb,et al.  Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. , 2007, Archives of dermatology.

[2]  S. Rogers,et al.  Two years of experience with etanercept in recalcitrant psoriasis , 2007, The British journal of dermatology.

[3]  A. Fischer,et al.  Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. , 2006, The Journal of allergy and clinical immunology.

[4]  J. Saurat,et al.  Cutaneous Adverse Events of Biological Therapy for Psoriasis: Review of the Literature , 2005, Dermatology.

[5]  E. Laffitte,et al.  Eczematous drug eruption after infliximab , 2004, The British journal of dermatology.

[6]  E. Zackai,et al.  T-cell homeostasis in humans with thymic hypoplasia due to chromosome 22q11.2 deletion syndrome. , 2004, Blood.

[7]  W. Shearer,et al.  Long-term assessment of T-cell populations in DiGeorge syndrome. , 2003, The Journal of allergy and clinical immunology.

[8]  I. Betlloch,et al.  Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. , 2002, Archives of dermatology.

[9]  A. Gennery,et al.  Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome , 2002, Archives of disease in childhood.

[10]  H. Yamagishi.  The 22q11.2 deletion syndrome. , 2002, The Keio journal of medicine.

[11]  R. Quinet,et al.  Etanercept and infliximab associated with cutaneous vasculitis. , 2002, Rheumatology.

[12]  E. Zackai,et al.  Lack of correlation between impaired T cell production, immunodeficiency, and other phenotypic features in chromosome 22q11.2 deletion syndromes. , 1998, Clinical immunology and immunopathology.